ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 257 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $33,538,201 | -21.5% | 940,763 | +1.5% | 0.07% | -18.1% |
Q2 2023 | $42,745,765 | +17.7% | 926,637 | +2.3% | 0.08% | +7.8% |
Q1 2023 | $36,311,553 | +133.7% | 905,525 | +170.0% | 0.08% | +120.0% |
Q4 2022 | $15,540,240 | +365.0% | 335,425 | +315.6% | 0.04% | +400.0% |
Q3 2022 | $3,342,000 | -84.1% | 80,714 | -77.0% | 0.01% | -83.7% |
Q2 2022 | $20,979,000 | -25.1% | 351,650 | -8.8% | 0.04% | -18.9% |
Q1 2022 | $27,993,000 | +42.1% | 385,453 | +64.6% | 0.05% | +47.2% |
Q4 2021 | $19,697,000 | +629.5% | 234,230 | +682.3% | 0.04% | +227.3% |
Q3 2021 | $2,700,000 | -20.3% | 29,942 | -15.7% | 0.01% | -26.7% |
Q2 2021 | $3,388,000 | -5.9% | 35,529 | +36.6% | 0.02% | -25.0% |
Q4 2020 | $3,601,000 | +8.2% | 26,014 | -12.3% | 0.02% | -35.5% |
Q4 2015 | $3,327,000 | -53.3% | 29,656 | -59.9% | 0.03% | -64.8% |
Q3 2015 | $7,126,000 | +16.1% | 73,993 | +23.4% | 0.09% | +10.0% |
Q2 2015 | $6,138,000 | -19.4% | 59,949 | -51.1% | 0.08% | -19.2% |
Q1 2015 | $7,613,000 | – | 122,613 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |